TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Behavioral and Brain Connectivity Analysis of Upper Limb Sensorimotor Rehabilitation Post Stroke: a Randomized Controlled Trial
Brief Summary: Stroke survivors often encounter impairments in the upper limb after stroke. Sensorimotor impairments are present in 67% of the stroke patients, resulting in problems with independency and performance of activities of daily life. In addition, the pattern of recovery in the brain is still a matter of ongoing debate. Although the importance of somatosensory function on motor performance is well described, evidence for somatosensory or sensorimotor therapy and brain-related changes is scares. Therefore, we aim to explore the effect of a sensorimotor therapy compared to pure motor therapy on motor function of the upper limb. A second objective is to investigate therapy-induced brain-behavior associations using resting state functional Magnetic Resonance Imaging of the brain.


Options:
A: Arm Label: sensorimotor therapy; Type: EXPERIMENTAL; Interventions: Other: additional sensorimotor therapy for the upper limb | Arm Label: motor therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: additional motor therapy for the upper limb after stroke | Intervention Type: OTHER; Name: additional sensorimotor therapy for the upper limb; Assigned to Arm(s): sensorimotor therapy | Intervention Type: OTHER; Name: additional motor therapy for the upper limb after stroke; Assigned to Arm(s): motor therapy
B: Arm Label: TMS and trunk rotation; Type: EXPERIMENTAL; Interventions: Device: TMS and trunk rotation | Arm Label: Sham TMS and trunk rotation; Type: SHAM_COMPARATOR; Interventions: Device: Sham TMS and trunk rotation | Intervention Type: DEVICE; Name: TMS and trunk rotation; Assigned to Arm(s): TMS and trunk rotation | Intervention Type: DEVICE; Name: Sham TMS and trunk rotation; Assigned to Arm(s): Sham TMS and trunk rotation
C: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Behavioral: Active Intervention, Behavioral: Placebo Intervention | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Behavioral: Active Intervention, Behavioral: Placebo Intervention | Intervention Type: BEHAVIORAL; Name: Active Intervention; Assigned to Arm(s): Group A, Group B | Intervention Type: BEHAVIORAL; Name: Placebo Intervention; Assigned to Arm(s): Group A, Group B
D: Arm Label: Sham tDCS plus RTP; Type: SHAM_COMPARATOR; Interventions: Device: Sham tDCS | Arm Label: Active tDCS plus RTP; Type: ACTIVE_COMPARATOR; Interventions: Device: Active tDCS | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Sham tDCS plus RTP | Intervention Type: DEVICE; Name: Active tDCS; Assigned to Arm(s): Active tDCS plus RTP

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A PROMs Based Educational Tool (PROM-DA) for Patients Considering Total Knee Arthroplasty: Development and a Pilot Randomized Controlled Trial.
Brief Summary: The primary objectives of this study are to: 1) develop an educational tool known as the Patient Reported Outcome Measure informed Decision Aid (PROM-DA) that will describe the options for patients considering total knee arthroplasty (TKA) surgery, and help them imagine what to expect if they choose either option; 2) assess the extent that the PROM-DA improves patients decision quality; 3) determine the feasibility of a larger trial to test the PROM-DA in multiple sites and more patients.


Options:
A: Arm Label: Check Yourself App With Feedback; Type: EXPERIMENTAL; Interventions: Behavioral: Check Yourself App with Feedback | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Check Yourself App with Feedback; Assigned to Arm(s): Check Yourself App With Feedback
B: Arm Label: Treatment Group; Type: EXPERIMENTAL; Interventions: Behavioral: Baseline and Follow-up Surveys, Other: Patient Reported Outcome Measure informed Decision Aid | Arm Label: Non Treatment Group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Baseline and Follow-up Surveys, Other: Pamphlet | Intervention Type: BEHAVIORAL; Name: Baseline and Follow-up Surveys; Assigned to Arm(s): Non Treatment Group, Treatment Group | Intervention Type: OTHER; Name: Patient Reported Outcome Measure informed Decision Aid; Assigned to Arm(s): Treatment Group | Intervention Type: OTHER; Name: Pamphlet; Assigned to Arm(s): Non Treatment Group
C: Arm Label: PHR Group; Type: ACTIVE_COMPARATOR; Interventions: Other: SANOIA Website | Arm Label: Non-PHR Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: SANOIA Website; Assigned to Arm(s): PHR Group
D: Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: quality of life pathway | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo control | Intervention Type: BEHAVIORAL; Name: quality of life pathway; Assigned to Arm(s): intervention group | Intervention Type: OTHER; Name: placebo control; Assigned to Arm(s): control group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: GP Practice Based Pharmacist Input to Medicines Optimisation
Brief Summary: The study is a United Kingdom (UK) based multi-centre study which will evaluate the impact of a medication optimisation intervention (delivered in GP practices by pharmacists to patients at risk of medication related problems), on healthcare resource utilisation and patient outcomes. Pharmacists in 4 areas across the UK (3 in England and 1 in Northern Ireland) will engage with patients, thought to be at a higher risk of medication related problems, within their GP practice in order to help identify areas for improvement


Options:
A: Arm Label: STRIPA intervention; Type: EXPERIMENTAL; Interventions: Device: STRIPA intervention | Arm Label: Sham intervention; Type: SHAM_COMPARATOR; Interventions: Other: Sham intervention | Intervention Type: DEVICE; Name: STRIPA intervention; Assigned to Arm(s): STRIPA intervention | Intervention Type: OTHER; Name: Sham intervention; Assigned to Arm(s): Sham intervention
B: Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Other: Medicines optimisation | Intervention Type: OTHER; Name: Medicines optimisation; Assigned to Arm(s): Intervention arm
C: Arm Label: Multidisciplinary medication review; Type: EXPERIMENTAL; Interventions: Procedure: Multidisciplinary medication review | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Multidisciplinary medication review; Assigned to Arm(s): Multidisciplinary medication review
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Other: Optimization strategy (complex intervention) | Intervention Type: OTHER; Name: Optimization strategy (complex intervention); Assigned to Arm(s): Intervention arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Teledermatology Mobile Apps: Implementation and Impact on Veterans' Access to Dermatology
Brief Summary: This study was designed to measure the impact of two teledermatology apps to provide direct to patient teledermatology follow up care, Patient Viewer and My VA Images, with a trial on access to dermatology care. The overall hypothesis was that sites implementing Department of Veterans Affairs' (VA) teledermatology mobile apps would significantly augment the use of teledermatology and improve Veterans' access to skin care relative to control sites. Specifically, the investigators hypothesized that these apps would improve established patients' ability to follow-up with dermatology care remotely, reducing patient travel to dermatology clinics while opening up dermatology clinic space for other patients. Due to a lack of participation by sites during the study which was conducted during the novel coronavirus (COVID-19) pandemic, the groups examined are Veterans who live in rural areas compared to those in urban areas.

Previously the study included a parallel trial to evaluate another teledermatology mobile app, VA Telederm. This trial was no longer feasible within this study's funding timeline due to limitations imposed on the mobile app by Office of Information \& Technology that were not under the control of the PI or the operational partner, Office of Connected Care (OCC).


Options:
A: Arm Label: Conventional EMS physician; Type: ACTIVE_COMPARATOR; Interventions: Other: conventional EMS physician | Arm Label: Tele-EMS physician; Type: OTHER; Interventions: Other: tele-EMS physician | Intervention Type: OTHER; Name: conventional EMS physician; Assigned to Arm(s): Conventional EMS physician | Intervention Type: OTHER; Name: tele-EMS physician; Assigned to Arm(s): Tele-EMS physician
B: Arm Label: Rural Veterans; Type: N/A; Interventions: Other: Direct to patient facing mobile apps introduction | Arm Label: Nonrural Veterans; Type: N/A; Interventions: Other: Direct to patient facing mobile apps introduction | Intervention Type: OTHER; Name: Direct to patient facing mobile apps introduction; Assigned to Arm(s): Nonrural Veterans, Rural Veterans
C: Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Procedure: Ophthalmic Telemedicine | Arm Label: Traditional Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Ophthalmic Telemedicine; Assigned to Arm(s): Telemedicine
D: Arm Label: Control; Type: OTHER; Interventions: Other: Control | Arm Label: CCH Model; Type: EXPERIMENTAL; Interventions: Other: Collaborative Connected health, (CCH) | Intervention Type: OTHER; Name: Collaborative Connected health, (CCH); Assigned to Arm(s): CCH Model | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Avoiding Anticoagulation After IntraCerebral Haemorrhage
Brief Summary: Randomised controlled trials (RCTs) demonstrate a substantial benefit from oral anticoagulant drugs for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation (AF). However, these RCTs excluded patients with prior intracerebral haemorrhage (ICH). Therefore, guidelines are unable to recommend whether oral anticoagulant drugs, in particular non-vitamin K antagonist (called direct OAC) - can be used for patients with AF after an intracerebral haemorrhage.

Roughly 30% of adults with ICH have AF but in 2017 it remains unclear whether they should start oral anticoagulant drugs, be treated with left atrial appendage closure (LAAC) or avoid anticoagulation and LAAC.


Options:
A: Arm Label: Direct Oral Anticoagulant (DOAC); Type: EXPERIMENTAL; Interventions: Drug: Apixaban 5 MG | Arm Label: Left Atrial Appendage Closure (LAAC); Type: EXPERIMENTAL; Interventions: Device: left atrial appendage closure | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Apixaban 5 MG; Assigned to Arm(s): Direct Oral Anticoagulant (DOAC) | Intervention Type: DEVICE; Name: left atrial appendage closure; Assigned to Arm(s): Left Atrial Appendage Closure (LAAC)
B: Arm Label: Apixaban; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Avoiding oral anticoagulants; Type: OTHER; Interventions: Drug: Aspirin, Drug: Carbasalate calcium, Drug: Clopidogrel, Drug: Dipyridamole, Other: No antithrombotic treatment | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Avoiding oral anticoagulants | Intervention Type: DRUG; Name: Carbasalate calcium; Assigned to Arm(s): Avoiding oral anticoagulants | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Avoiding oral anticoagulants | Intervention Type: DRUG; Name: Dipyridamole; Assigned to Arm(s): Avoiding oral anticoagulants | Intervention Type: OTHER; Name: No antithrombotic treatment; Assigned to Arm(s): Avoiding oral anticoagulants
C: Arm Label: Edoxaban 60/30mg daily; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban | Arm Label: Non-anticoagulant medical therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-anticoagulant medical therapy | Intervention Type: DRUG; Name: Edoxaban; Assigned to Arm(s): Edoxaban 60/30mg daily | Intervention Type: OTHER; Name: Non-anticoagulant medical therapy; Assigned to Arm(s): Non-anticoagulant medical therapy
D: Arm Label: LAAO group; Type: EXPERIMENTAL; Interventions: Device: Left atrial appendage closure | Arm Label: NOAC group; Type: EXPERIMENTAL; Interventions: Drug: NOAC | Intervention Type: DRUG; Name: NOAC; Assigned to Arm(s): NOAC group | Intervention Type: DEVICE; Name: Left atrial appendage closure; Assigned to Arm(s): LAAO group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Shared Medical Decision Making in the Prophylactic Treatment of Bipolar Disorder
Brief Summary: The investigators hypothesize that implementation of a shared decision making care plan for prophylactic treatment will help therapeutic adherence of bipolar patients. They also anticipate that patients treated according to a shared decision making plan will have an elevated satisfaction of their care, quality of life and functionment, as well as a lower number of relapses


Options:
A: Arm Label: Method Guided Self-Determination; Type: EXPERIMENTAL; Interventions: Behavioral: Guided Self-Determination GSD | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Guided Self-Determination GSD; Assigned to Arm(s): Method Guided Self-Determination
B: Arm Label: RQP-MH; Type: EXPERIMENTAL; Interventions: Behavioral: Right Question Project - Mental Health (RQP-MH) | Arm Label: Comparison Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Pamphlet | Intervention Type: BEHAVIORAL; Name: Right Question Project - Mental Health (RQP-MH); Assigned to Arm(s): RQP-MH | Intervention Type: BEHAVIORAL; Name: Pamphlet; Assigned to Arm(s): Comparison Group
C: Arm Label: SDM care planning; Type: EXPERIMENTAL; Interventions: Other: Shared Decision-Making educational training | Intervention Type: OTHER; Name: Shared Decision-Making educational training; Assigned to Arm(s): SDM care planning
D: Arm Label: Shared Decision making for care; Type: N/A; Interventions: Other: Shared-decision making process | Arm Label: Standard decision making for care; Type: N/A; Interventions: Other: standard care | Intervention Type: OTHER; Name: Shared-decision making process; Assigned to Arm(s): Shared Decision making for care | Intervention Type: OTHER; Name: standard care; Assigned to Arm(s): Standard decision making for care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Transplant Medication Safety Through A Pharmacist-Empowered, Patient-Centered, Mhealth-Based Intervention (TRANSAFE Rx Study)
Brief Summary: TRANSAFE Rx is a 12-month, parallel two-arm, 1:1 randomized controlled clinical trial, involving 136 participants (68 in each arm) measuring the clinical and economic effectiveness of a pharmacist-led intervention, which utilizes an innovative mHealth application to improve medication safety and health outcomes, as compared to usual post-transplant care. The primary goal of the TRANSAFE Rx study is to demonstrate significant reductions in med safety issues leading to reduced healthcare resource utilization in kidney transplantation through a pharmacist-led, mHealth-enabled, intervention. This study will provide detailed and novel information on the incidence, etiologies and outcomes of med errors and adverse drug events in this high-risk population; while also demonstrating the effectiveness of this intervention on reducing the incidence and impact of med safety issues in kidney transplantation.


Options:
A: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: mHealth; Type: EXPERIMENTAL; Interventions: Behavioral: mHealth | Intervention Type: BEHAVIORAL; Name: mHealth; Assigned to Arm(s): mHealth
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: TAKE IT Strategy | Intervention Type: BEHAVIORAL; Name: TAKE IT Strategy; Assigned to Arm(s): Intervention
C: Arm Label: mHealth Group; Type: EXPERIMENTAL; Interventions: Other: Pharmacist-led medication therapy using mHealth application | Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pharmacist-led medication therapy using mHealth application; Assigned to Arm(s): mHealth Group
D: Arm Label: Tacrolimus twice-daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus twice daily | Arm Label: Envarsus XR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Envarsus XR | Intervention Type: DRUG; Name: Envarsus XR; Assigned to Arm(s): Envarsus XR | Intervention Type: DRUG; Name: Tacrolimus twice daily; Assigned to Arm(s): Tacrolimus twice-daily

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of the Perineal Physiotherapy in the Prevention and Treatment of Pelvic Floor Dysfunction in Postpartum
Brief Summary: Objective: To find out the effectiveness of pelvic-perineal physiotherapy in prevention and treatment of postpartum pelvic floor dysfunction caused by vaginal delivery.


Options:
A: Arm Label: Group Bladder Training; Type: EXPERIMENTAL; Interventions: Other: Bladder Training | Arm Label: Group TMAP; Type: ACTIVE_COMPARATOR; Interventions: Other: TMAP | Arm Label: Group Bladder Training + TMAP; Type: ACTIVE_COMPARATOR; Interventions: Other: Bladder Training + TMAP | Intervention Type: OTHER; Name: Bladder Training; Assigned to Arm(s): Group Bladder Training | Intervention Type: OTHER; Name: TMAP; Assigned to Arm(s): Group TMAP | Intervention Type: OTHER; Name: Bladder Training + TMAP; Assigned to Arm(s): Group Bladder Training + TMAP
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Darifenacin | Arm Label: 2; Type: OTHER; Interventions: Drug: Darifenacin, Behavioral: Behavioral therapy | Intervention Type: DRUG; Name: Darifenacin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Darifenacin; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Behavioral therapy; Assigned to Arm(s): 2
C: Arm Label: PFMT&HE group; Type: EXPERIMENTAL; Interventions: Other: PFM training, Other: HE, Behavioral: Educational strategy | Arm Label: HE group; Type: EXPERIMENTAL; Interventions: Other: HE, Behavioral: Educational strategy | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational strategy | Intervention Type: OTHER; Name: PFM training; Assigned to Arm(s): PFMT&HE group | Intervention Type: OTHER; Name: HE; Assigned to Arm(s): HE group, PFMT&HE group | Intervention Type: BEHAVIORAL; Name: Educational strategy; Assigned to Arm(s): Control group, HE group, PFMT&HE group
D: Arm Label: G1; Type: EXPERIMENTAL; Interventions: Procedure: Pregnants for receive the physical therapy guide | Intervention Type: PROCEDURE; Name: Pregnants for receive the physical therapy guide; Assigned to Arm(s): G1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: GASTROKE- the Effect of General Anesthesia Versus Sedation for Patients With Acute Ischemic STROKE Undergoing Endovascular Treatment on Three Month Morbidity and Mortality: a Feasibility Study.
Brief Summary: After a stroke caused by a blockage (clot) in a blood vessel in the brain, patients may have the clot removed by threading a catheter from the groin up to the affected area of the brain. An anesthesiologist is involved in the patient's care during this procedure to maximize patient safety and procedural efficiency. The options for anesthesia for this procedure are general anesthesia (where the patient is unconscious) or sedation (where the patient is in a relaxed, calm, sleepy condition). Currently, it is unclear which of these anesthetic options contributes to the best patient outcome. The investigators would like to investigate whether or not one method of anesthesia (general or sedation) is better to use than the other when removing the clot.


Options:
A: Arm Label: General Anesthesia; Type: EXPERIMENTAL; Interventions: Drug: General Anesthesia | Arm Label: Conscious Sedation with Remifentanil; Type: EXPERIMENTAL; Interventions: Drug: Conscious Sedation with Remifentanil | Intervention Type: DRUG; Name: General Anesthesia; Assigned to Arm(s): General Anesthesia | Intervention Type: DRUG; Name: Conscious Sedation with Remifentanil; Assigned to Arm(s): Conscious Sedation with Remifentanil
B: Intervention Type: DRUG; Name: rt-PA 0.9 mg/kg verum or placebo Intravenous; Assigned to Arm(s): N/A
C: Arm Label: General Anesthesia; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Local Anesthesia; Type: EXPERIMENTAL; Interventions: Procedure: Local anesthesia | Intervention Type: PROCEDURE; Name: Local anesthesia; Assigned to Arm(s): Local Anesthesia
D: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure

Answer: A